MedTrace Logo

Pediatric Ketamine Study for Pain Management

NCT02388321 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2018-05-08

Study results available
· View outcomes & findings →

Summary

Direct comparison of intranasal sub-dissociative dose ketamine with intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.

Conditions

Interventions

DRUG

Ketamine

intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.

DRUG

Fentanyl

intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.

Sponsors & Collaborators

  • Maimonides Medical Center

    collaborator OTHER

  • Antonios Likourezos

    lead OTHER

Principal Investigators

  • Sabina Zavolkovskaya, MD · Maimonides Medical Center

  • Sergey Motov, MD · Maimonides Medical Center

  • John Marshall, MD · Maimonides Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-01
Primary Completion
2016-12-31
Completion
2017-10-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02388321 on ClinicalTrials.gov